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Recent studies have shown that interferon-gamma (IFN-g) synergizes with IFN-a/h to inhibit the replication of both RNA and
DNA viruses. We investigated the effects of IFNs on the replication of two strains of severe acute respiratory syndrome-associated
coronavirus (SARS-CoV). While treatment of Vero E6 cells with 100 U/ml of either IFN-h or IFN-g marginally reduced viral
replication, treatment with both IFN-h and IFN-g inhibited SARS-CoV plaque formation by 30-fold and replication by 3000-fold
at 24 h and by N 1  105-fold at 48 and 72 h post-infection. These studies suggest that combination IFN treatment warrants
further investigation as a treatment for SARS.
D 2004 Elsevier Inc. All rights reserved.
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Severe acute respiratory syndrome (SARS) is a newly
recognized illness that spread from southern China in late
2002/early 2003 to several countries in Asia, Europe and
North America (Guan et al., 2003). SARS usually begins with
a fever greater than 38 8C. Initial symptoms can also include
headache, malaise, and mild respiratory symptoms. Within 2
days to a week, SARS patients may develop a dry cough and
have trouble breathing. Patients in more advanced stages of
SARS develop either pneumonia or respiratory distress
syndrome. In the initial outbreak, there were 8098 cases
worldwide, with an overall mortality of 9.6% (http://0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.08.011
* Corresponding author. Department of Microbiology and Immuno-
logy, University of Texas Medical Branch, 301 University Boulevard,
G.150 Keiller Building, Galveston, TX 77555-0609. Fax: +1 409 747 2545.
E-mail address: ecmossel@utmb.edu (E.C. Mossel).www.who.int/csr/sars/en/). A previously unrecognized coro-
navirus (CoV) has been demonstrated to be the cause of the
new disease (Drosten et al., 2003; Ksiazek et al., 2003; Peiris
et al., 2003). In a remarkably short period of time, the entire
genetic sequences of several strains of the novel SARS-CoV
were determined and the virion receptor identified (Li et al.,
2003). Similar CoV have been isolated from civets and other
animals that are trapped for food or medicine at live animal
markets in Guangdong province China, the presumed epi-
center of the outbreak (Guan et al., 2003). SARS-CoV or a
closely related CoV also infects animals in the wild and
appears to have entered the human population in the past
(Zheng et al., 2004).
Current strategies for the treatment of SARS patients
have included broad-spectrum antibiotics, glucocorticoids
and ribavirin (Fujii et al., 2004); however, the efficacy of
these treatments is still unclear. Therefore, to develop
better treatment strategies for future outbreaks, it is
imperative to understand the relationship between the004) 11–17
Rapid Communication12virus and the host immune system. Type I IFNs (IFN-a
and IFN-h) and type II IFN (IFN-g) are important
components of the host immune response to viral
infections. IFN-a and IFN-h are produced by most cells
as a direct response to viral infection, while IFN-g is
synthesized almost exclusively by activated natural killer
(NK) cells and activated T cells in response to virus-
infected cells (Pfeffer et al., 1998). Both types of IFNs
achieve their antiviral effects by inducing the synthesis of
several proteins that interfere with viral replication
(Goodbourn et al., 2000). Several studies have examined
the anti-viral effects of IFNs against SARS-CoV.
Although results from clinical studies using IFN-a are
inconclusive (Haagmans et al., 2004; Loutfy et al., 2003),
in vitro studies strongly suggest that IFN-h at concen-
trations greater than 1000 U/ml can marginally inhibit the
replication of SARS-CoV (Cinatl et al., 2003; Hensley
et al., 2004; Spiegel et al., 2004; Stroher et al., 2004).
Likewise, analysis of cytokine levels in SARS patients
suggests that the presence of IFN-g at the early stages of
disease onset correlates with resolution of the viral
infection (D. Kelvin and M. Cameron, personal commu-
nication); however, IFN-g has little antiviral effect against
SARS-CoV in vitro (Cinatl et al., 2003; Spiegel et al.,
2004). Recent studies examining the anti-viral effects of
IFNs against both RNA and DNA viruses have shown
that when used in combination, IFN-g synergizes with
the innate IFNs (IFN-a and IFN-h) to inhibit the
replication of viruses such as herpes simplex virus
type-1 (Sainz and Halford, 2002), hepatitis C virus
(Larkin et al., 2003), Lassa virus (Asper et al., 2004),
and cytomegalovirus (Sainz et al., unpublished data). To
further test this principle, we examined the antiviral
effects of recombinant IFN-h and/or IFN-g against
SARS-CoV replication in vitro.Table 1













IFN-h (100) + IFN-g (100)
a Vero E6 cells were treated with vehicle, hu IFN-h, hu IFN-g or hu IFN-h and hu
strain Urbani. L2 cells received identical treatments with murine IFNs and were
b Average number of plaques per well of a 105 diluted stock determined 3–4 days p
experiments.
c Fold-reduction in each group was calculated as ’plaques in vehicle/plaques i
Boldface type indicates a greater than 30-fold reduction in viral plaque formation
* P b 0.05, as determined by one-way ANOVA and Tukey’s post hoc t test comResults
IFN-b and IFN-c synergistically inhibit SARS-CoV plaque
formation
The capacity of human IFN-h and/or IFN-g to inhibit the
replication of SARS-CoV (strain Urbani) was initially
compared in a plaque reduction assay on Vero E6 cells. In
cultures pre-treated with 100 U/ml of IFN-h or IFN-g alone,
SARS-CoV formed an average of 14 and 15 plaques,
respectively (Table 1). The level of inhibition achieved with
either type I or type II IFN treatment as compared to vehicle-
treated cultures was V3-fold. In contrast, the level of
inhibition achieved in cultures pre-treated with a combination
of type I and type II IFNs was significantly greater (P b
0.001). In cultures treated with 100 U/ml of both IFN-h and
IFN-g, SARS-CoV plaque formation was inhibited by 30-
fold, yielding an average of approximately 2 plaques. The
level of inhibition achieved with combination IFN-h and
IFN-g treatment was not a consequence of doubling the
amount of IFN per culture, as increasing the concentration of
IFN in individually treated IFN groups to 200 U/ml did not
achieve a similar inhibitory effect (Table 1).
We also tested the relevance of this phenomenon by
comparing the antiviral effect of IFN-h and IFN-g treatment
against another strain of SARS-CoV (strain Hong Kong; HK)
and against the murine hepatitis virus (MHV) strain A59, an
unrelated member of the Coronaviridae family. Consistent
with the result obtained for the Urbani strain (Table 1),
combination IFN-h and IFN-g treatment inhibited HK plaque
formation by greater than 40-fold (data not shown). Interest-
ingly, the effect of IFNs on MHV-A59 plaque formation was
significantly different. While the level of inhibition achieved
with either IFN-h or IFN-g treatment alone was approx-
imately 2-fold, combination IFN-h and IFN-g treatmentMean no. plaquesb F SEM Fold-reductionc
40.3 F 5.9 –
14 F 4.8* 3
15 F 1.0* 2
19.3 F 5.8* 2
11.5 F 1.0* 3
1.8 F 0.5* 30
60.3 F 1.8 –
24.7 F 1.1* 2
21.0 F 0.7* 2
32.0 F 0.8* 2
27.7 F 1.1* 2
9.7 F 1.1* 6
IFN-g for 12 h before infection with approximately 40 PFU of SARS-CoV
infected with approximately 50 PFU of MHV-A59.
ost-infection (p.i.). Values represent (meanF SEM) from three independent
n treatment.’ Values represent mean from three independent experiments.
.
parison of this treatment to vehicle.
Rapid Communication 13inhibited MHV-A59 plaque formation on L2 cells by only 6-
fold (Table 1).
Fig. 1 shows a representative photograph of SARS-CoV
plaque formation on IFN-treated Vero E6 cells 4 days post-
infection (p.i.). Consistent with the experimental results
summarized in Table 1, SARS-CoV plaque efficiency was
inhibited in cultures treated with both IFN-h and IFN-g
(Fig. 1D). In addition, while plaque morphology in vehicle-,
IFN-h- or IFN-g-treated cells averaged 2 to 4 mm in size,
plaques observed in cultures treated with both IFN-h and
IFN-g were consistently smaller, averaging V 1 mm in size
(Fig. 1A vs. 1D).
IFN-b and IFN-c synergistically inhibit SARS-CoV
replication
To further characterize the inhibitory effect of IFN-h and
IFN-g treatment on SARS-CoV replication, three-day viral
growth assays were performed. Vero E6 cells were pre-treated
for 12 h with 100 U/ml of IFNs separately or in combination,
infected with SARS-CoV (Urbani or HK strain) at a MOI of
0.01 PFU per cell, and culture supernatants were titered for
infectious virus at 24, 48 and 72 h p.i. In cultures treated with
100 U/ml of IFN-h or IFN-g, Urbani and HK replication was
significantly inhibited (P b 0.001) at 24 and 48 h p.i., with the
greatest level of inhibition observed in IFN-h treated cultures
(Figs. 2A, B). At 72 h p.i. however, viral titers in IFN-h- or
IFN-g-treated cultures approached levels of that detected in
vehicle-treated groups (Figs. 2A, B). Relative to vehicleFig. 1. IFN-h and/or IFN-g inhibit SARS-CoV plaque formation on Vero
E6 cells. Cultures were pre-treated for 12 h with (A) vehicle or 100 U/ml
each of (B) IFN-h, (C) IFN-g or (D) IFN-h and IFN-g before infection.
Monolayers were inoculated with variable titers SARS-CoV to produce
numerous visible plaques. Plaque numbers in this figure do not correspond
to quantitative data presented in Table 1. Cells were stained with neutral red
3 days p.i. and cultures were photographed 24 h later.control cultures, viral titers recovered at 72 h p.i. from
cultures treated with either IFN-h or IFN-g were reduced by
3-fold in Urbani-infected cultures (Fig. 2D), and 5- and 2-
fold in HK-infected cultures, respectively (Fig. 2E). As
with our plaque reduction assays, we observed a potent
inhibitory effect when Vero cultures were treated with both
IFN-h and IFN-g. Compared to viral titers of greater than
1  105 PFU/ml in vehicle-treated cells, in cultures treated
with 100 U/ml each of IFN-h and IFN-g, Urbani replicated
to titers of 55, 11 and 6 PFU/ml at 24, 48 and 72 h p.i.,
respectively (Fig. 2A), and HK replicated to titers 324, 79
and 17 PFU/ml at 24, 48 and 72 h p.i., respectively (Fig.
2B). The inhibitory effect achieved with combination IFN-
h and IFN-g treatment was consistently greater than 3000-
fold at all time points tested and reached levels of greater
than 1  105-fold at 72 h p.i. relative to vehicle treated
Vero E6 cells (Figs. 2D, E). In contrast, when tested
against MHV-A59, combination IFN-h and IFN-g treat-
ment showed only a 8-10-fold increased antiviral effect
when compared to cultures treated with IFN-h or IFN-g
separately (Figs. 2C, F). Similar results were obtained on
17CL-1 cells (data not shown). Although this result would
suggest that the synergistic antiviral effect observed in
cultures treated with both IFN-h and IFN-g is specific to
SARS-CoV, we cannot exclude the possibility that the
effect observed with regards to MHV plaque formation and
replication is cell type-specific.
The degree of cytopathic effect (CPE) in cultures treated
with IFNs was also examined. CPE was extensive in
vehicle-treated groups infected with either Urbani or HK
at 120 h p.i. (Figs. 3A, E), as evident by the reduced number
of cells present following staining with crystal violet.
However, varying degrees of CPE were observed in IFN-
treated cultures. For example, the extent of CPE observed in
IFN-g-treated cultures at 120 h p.i. (Figs. 3C, G) was
considerably less than the extent of CPE observed in IFN-h-
treated cultures at 120 h p.i. (Figs. 3B, F). This observation
is surprising as the levels of viral titers recovered from both
IFN-h- and IFN-g-treated cultures at 72 h (Figs. 2A, B) and
120 h (data not shown) p.i. were similar. Moreover, as
compared to vehicle-treated and individually IFN-treated
cultures, the degree of CPE observed in cells treated with
both IFN-h and IFN-g is less evident at 120 h p.i., and
monolayers appeared evenly stained with little to no visible
CPE (Figs. 3D, H). This observation is consistent with the
level of viral titers recovered from these cultures at 120 h
p.i. (data not shown).Discussion
In previous studies examining the antiviral effects of
IFNs against SARS-CoV replication in vitro, the antiviral
effect of IFN treatment varied based on the concentration
and type of IFN. Studies examining the antiviral efficacy of
IFN-h alone against SARS-CoV replication showed levels
Fig. 2. IFN-h and/or IFN-g inhibit SARS-CoV replication in Vero E6 Cells. Vero E6 or L2 cells were treated with (n) vehicle or 100 U/ml each of (.) IFN-h,
(E) IFN-g or (w) IFN-h and IFN-g 12 h before infection with SARS-CoV strain (A, D) Urbani, SARS-CoV strain (B, E) HK or (C, F) MHV-A59 at a MOI of
0.01 PFU per cell. Supernatants were harvested on the indicated days p.i., and viral titers were determined by plaque assay as described in Materials and
methods. Significant differences in viral titers in Vero E6 cells treated with IFNs relative to cells treated with vehicle are denoted by a single asterisk ( P b
0.001, one-way ANOVA and Tukey’s post hoc t test). (D–F) Average fold inhibition in viral replication observed in cells treated 100 U/ml each of ( ) IFN-h,
(5) IFN-g or (n) IFN-h and IFN-g was calculated as (average viral titers in vehicle-treated/average viral titers in IFN-treated). One-way ANOVA followed by
Tukey’s post hoc t test confirmed that the fold-inhibition of SARS-CoV by combination IFN-h and IFN-g was highly significant ( P b 0.001) at all time points
tested.
Rapid Communication14of inhibition averaging V 1000-fold at concentration of
1000 U/ml or greater (Cinatl et al., 2003; Hensley et al.,
2004; Spiegel et al., 2004). Likewise, similar effects were
seen with IFN-a treatment (Stroher et al., 2004); however,
IFN-g was shown to be an ineffective inhibitor of SARS-CoV replication (Cinatl et al., 2003; Spiegel et al., 2004).
The results of the present study, however, demonstrate that
as little as 100 U/ml each of IFN-h and IFN-g can potently
inhibit SARS-CoV replication by 1  105-fold. The
inhibitory effect observed was measured at the level of
Fig. 3. IFN-h and/or IFN-g inhibit SARS-CoV replication in Vero E6 cells. Cultures were pre-treated for 12 h with (A, E) vehicle or 100 U/ml each of (B, F)
IFN-h, (C, G) IFN-g or (D, H) IFN-h and IFN-g before infection with SARS-CoV strains Urbani (A-D) or HK (E-H) at a MOI of 0.01 PFU/cell. Monolayers
were fixed, stained with crystal violet and photographed 120 h p.i.
Rapid Communication 15viral plaque formation (Table 1) and replication (Fig. 2), and
the results presented herein indicate that: (1) the effect is far
greater than additive, (2) maintainable up to 120 h p.i.
(maximum length of time tested) and (3) effective against
two strains of SARS-CoV and not against MHV.
If the potent inhibitory effect observed in cultures treated
with both IFN-h and IFN-g were synergistic in nature, the
data would fit the inequalities of synergism described
Berenbaum (Berenbaum, 1989). For example, a synergistic
relationship would exist if the level of inhibition achieved
with 100 U/ml of IFN-h plus 100 U/ml of IFN-g were
significantly greater than the level of inhibition achieved with
200 U/ml of either IFN-h or IFN-g separately. The plaque
reduction data presented in Table 1 support this inequality
and suggest a synergistic antiviral relationship between type I
and type II IFNs with regards to SARS-CoV plaque
formation. Likewise, the fold-inhibition data presented in
Fig. 2 strongly supports the hypothesis that IFN-h and IFN-g
synergistically inhibit the replication of SARS-CoV. Specif-
ically, if the observed effect were additive, then the level of
inhibition in viral replication predicted for cultures treated
with 100U/ml of both IFN-h and IFN-gwould be equal to the
sum of the level of inhibition achieved in culture treated with
100 U/ml of IFN-h and IFN-g separately. For both Urbani
and HK (Figs. 2D, E), the level of inhibition achieved in
cultures treated with 100 U/ml of both IFN-h and IFN-g was
approximately 1000 times greater than the sum of the fold-
inhibition achieved in cultures treated with 100 U/ml of IFN-
h and IFN-g separately (Pb0.001). More extensive syner-
gistic analyses will need to be conducted to formally prove
synergy; however, the data presented herein strongly argue in
favor of this hypothesis.
Interestingly, the degree of CPE observed in cultures
treated with either IFN-h or IFN-g differed, although thelevel of viral replication in both treatment groups was similar
(Fig. 3 vs. Figs. 2A, B). We hypothesize that the difference in
CPE may be reflective of the different IFN pathways used by
each IFN respectively, and may be an essential factor when
considering the mechanism by which IFN-h and IFN-g
synergistically inhibit SARS-CoV replication. Type I IFNs
(IFN-a and IFN-h) and type II IFN (IFN-g) activate distinct
but related Jak/STAT signal cascades resulting in the tran-
scription of several hundred IFN-stimulated genes (Good-
bourn et al., 2000). Although similar genes are activated by
all three IFNs, Der, et al. have identified numerous genes
differentially regulated by IFN-a, IFN-h or IFN-g using
oligonucleotide arrays (Der et al., 1998). In particular, IFN-
h stimulation resulted in the identification of twice as many
genes as compared to IFN-g. This differential regulation of
IFN-induced genes may explain in part the synergistic effect
achieved with both IFN-h and IFN-g. It remains to be
determined, however, the profile of different IFN-stimulated
genes present in cells treated with both type I and type II
IFNs.
Public health interventions, such as surveillance, travel
restrictions and quarantines, contained the original spread of
SARS-CoV in 2003 and again appear to have stopped the
spread of SARS after the appearance of a few new cases in
2004. It is unknown, however, whether these draconian
containment measures can be sustained with each appearance
of the SARS-CoV in humans. The immune response to
SARS-CoV infection appears capable of clearing the
infection in most individuals. By reducing SARS-CoV load
it may be possible to extend the window of time during which
an effective immune response could arise. Thus, treatments
that reduce SARS-CoV load by several logs in infected
individuals could enable more individuals to control,
eliminate and survive SARS-CoV infections. Combination
Rapid Communication16IFN treatment therefore warrants further consideration as a
treatment for SARS.Materials and methods
Cells, viruses and interferons
Vero E6 and L2 cells (American Type Culture Collection,
Manassas, VA) were maintained in minimum essential
medium (MEM) or Dulbecco modified Eagle medium
(DMEM), respectively, and supplemented with 5% fetal
bovine serum (FBS), penicillin G (100 U/ml), streptomycin
(100 mg/ml) and 2 mM L-glutamine, at 37 8C in 5% CO2.
SARS-CoV strains Urbani and Hong Kong 3pm 02-7029,
hereafter called HK, were propagated in Vero E6 cells. MHV
strain A59 (ATCC, VR764) was propagated in L2 cells.
Recombinant human (hu) IFN-h, hu IFN-g, murine (mu)
IFN-h and mu IFN-g (PBL Biomedical Laboratories, New
Brunswick, NJ) were added to cell cultures 12 hs (h) before
infection and maintained after viral infection. For all
experiments described herein, hu IFNs were used exclu-
sively on Vero E6 cells while mu IFNs were used to treat L2
cells. In addition, concentrations of 100 U/ml were used for
all experiments unless stated otherwise.
Viral plaque reduction assays
For plaque reduction assays, Vero E6 cells or L2 cells
were seeded at a density of 1  106 cells in each well of a 6-
well plate, and 24 h later, various doses of IFN-h and/or
IFN-g were added to the culture medium. After 12 h of IFN
treatment, medium was removed and monolayers were
infected with a fixed inoculum of SARS-CoV (strain Urbani
or HK) or MHV-A59. After 1 h adsorption, the inoculum
was removed, cells were washed twice with 1 phosphate
buffered saline, and then overlaid with 10% FBS/DMEM
containing 0.5% SeaPlaque Agarose (Cambrex Bio Science
Rockland, Inc., Rockland, ME) and the same IFN type and
concentration used during pre-treatment. Cells were stained
with neutral red 2 days p.i. (MHV) or 3 days p.i. (SARS-
CoV), and plaque numbers were determined 24 h later.
Viral replication assays
For virus replication assays, Vero E6 cells or L2 cells
were seeded at a density of 1  106 cells in each well of a 6-
well plate, and 24 h later, 100 U/ml of IFN-h and/or IFN-g
were added to the culture medium. After 12 h of IFN
treatment, cell monolayers were inoculated with SARS-CoV
(strain Urbani or HK) or MHV-A59 at a multiplicity of
infection (MOI) of 0.01 PFU per cell. After 1 h adsorption,
the inoculum was removed, monolayers were washed twice
with 1 phosphate buffered saline, and fresh IFN-contain-
ing culture medium was returned to each well. Twenty-four,
48 or 72 h p.i., titers of infectious virus in cell supernatantswas determined by a serial dilution plaque assay on Vero E6
cells for SARS-CoV or L2 cells for MHV.
Statistics
Data are presented as the means F standard error of the
means (sem). Data from IFN-treated groups were compared
to vehicle-treated groups and significant difference were
determined by one-way analysis of variance (ANOVA)
followed by Tukey’s post hoc t test (GraphPad Prism Home,
San Diego, CA).Acknowledgments
The authors would like to thank Dr. Li-Kuang Chen from
Tzu-Chi University at Hualien, Taiwan for kindly supplying
the SARS-CoV strain HK and Dr. Joseph A. Vaccaro for
critical review of this manuscript. This work was supported
by the National Institutes of Health (AI054626, AI054238,
RR018229, and CA08921; R.F.G.) and (NO1 AI 25489;
C.J.P.). Bruno Sainz is a recipient of a National Research
Service Award from the NIAID (AI0543818) and Dr. Eric
Mossel is a recipient of an Emerging and Re-emerging
Diseases Fellowship from the NIAID (AI007536).References
Asper, M., Sternsdorf, T., Hass, M., Drosten, C., Rhode, A., Schmitz, H.,
Gunther, S., 2004. Inhibition of different Lassa virus strains by alpha
and gamma interferons and comparison with a less pathogenic
arenavirus. J. Virol. 78 (6), 3162–3169.
Berenbaum, M.C., 1989. What is synergy? Pharmacol. Rev. 41 (2),
93–141.
Cinatl, J., Morgenstern, B., Bauer, G., Chandra, P., Rabenau, H., Doerr,
H.W., 2003. Treatment of SARS with human interferons. Lancet 362
(9380), 293–294.
Der, S.D., Zhou, A., Williams, B.R., Silverman, R.H., 1998. Identification
of genes differentially regulated by interferon alpha, beta, or gamma
using oligonucleotide arrays. Proc. Natl. Acad. Sci. U.S.A. 95 (26),
15623–15628.
Drosten, C., Gunther, S., Preiser, W., van der Werf, S., Brodt, H.R., Becker,
S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R.A., Berger,
A., Burguiere, A.M., Cinatl, J., Eickmann, M., Escriou, N., Grywna, K.,
Kramme, S., Manuguerra, J.C., Muller, S., Rickerts, V., Sturmer, M.,
Vieth, S., Klenk, H.D., Osterhaus, A.D., Schmitz, H., Doerr, H.W.,
2003. Identification of a novel coronavirus in patients with severe acute
respiratory syndrome. N. Engl. J. Med. 348 (20), 1967–1976.
(Electronic publication 2003 Apr 10.).
Fujii, T., Nakamura, T., Iwamoto, A., 2004. Current concepts in SARS
treatment. J. Infect. Chemother. 10 (1), 1–7.
Goodbourn, S., Didcock, L., Randall, R.E., 2000. Interferons: cell signal-
ling, immune modulation, antiviral response and virus countermeasures.
J. Gen. Virol. 81 (Pt. 10), 2341–2364.
Guan, Y., Zheng, B.J., He, Y.Q., Liu, X.L., Zhuang, Z.X., Cheung, C.L.,
Luo, S.W., Li, P.H., Zhang, L.J., Guan, Y.J., Butt, K.M., Wong, K.L.,
Chan, K.W., Lim, W., Shortridge, K.F., Yuen, K.Y., Peiris, J.S., Poon,
L.L., 2003. Isolation and characterization of viruses related to the
SARS coronavirus from animals in southern China. Science 302
(5643), 276–278. (Electronic publication 2003 Sep 4.).
Rapid Communication 17Haagmans, B.L., Kuiken, T., Martina, B.E., Fouchier, R.A., Rimmelzwaan,
G.F., van Amerongen, G., van Riel, D., de Jong, T., Itamura, S., Chan,
K.H., Tashiro, M., Osterhaus, A.D., 2004. Pegylated interferon-alpha
protects type 1 pneumocytes against SARS coronavirus infection in
macaques. Nat. Med. 10 (3), 290–293. (Electronic publication 2004
Feb 22.).
Hensley, L.E., Fritz, L.E., Jahrling, P.B., Karp, C.L., Huggins, J.W.,
Geisbert, T.W., 2004. Interferon-beta 1a and SARS coronavirus
replication. Emerging Infect. Dis. 10 (2), 317–319.
Ksiazek, T.G., Erdman, D., Goldsmith, C.S., Zaki, S.R., Peret, T., Emery,
S., Tong, S., Urbani, C., Comer, J.A., Lim, W., Rollin, P.E., Dowell,
S.F., Ling, A.E., Humphrey, C.D., Shieh, W.J., Guarner, J., Paddock,
C.D., Rota, P., Fields, B., DeRisi, J., Yang, J.Y., Cox, N., Hughes, J.M.,
LeDuc, J.W., Bellini, W.J., Anderson, L.J., 2003. A novel coronavirus
associated with severe acute respiratory syndrome. N. Engl. J. Med. 348
(20), 1953–1966.
Larkin, J., Jin, L., Farmen, M., Venable, D., Huang, Y., Tan, S.L., Glass,
J.I., 2003. Synergistic antiviral activity of human interferon combina-
tions in the hepatitis C virus replicon system. J. Interferon Cytokine
Res. 23 (5), 247–257.
Li, W., Moore, M.J., Vasilieva, N., Sui, J., Wong, S.K., Berne, M.A.,
Somasundaran, M., Sullivan, J.L., Luzuriaga, K., Greenough, T.C.,
Choe, H., Farzan, M., 2003. Angiotensin-converting enzyme 2 is a
functional receptor for the SARS coronavirus. Nature 426 (6965),
450–454.
Loutfy, M.R., Blatt, L.M., Siminovitch, K.A., Ward, S., Wolff, B., Lho, H.,
Pham, D.H., Deif, H., LaMere, E.A., Chang, M., Kain, K.C., Farcas,G.A., Ferguson, P., Latchford, M., Levy, G., Dennis, J.W., Lai, E.K.,
Fish, E.N., 2003. Interferon alfacon-1 plus corticosteroids in SARS: a
preliminary study. JAMA 290 (24), 3222–3228.
Peiris, J.S., Lai, S.T., Poon, L.L., Guan, Y., Yam, L.Y., Lim, W., Nicholls,
J., Yee, W.K., Yan, W.W., Cheung, M.T., Cheng, V.C., Chan, K.H.,
Tsang, D.N., Yung, R.W., Ng, T.K., Yuen, K.Y., 2003. Coronavirus as a
possible cause of severe acute respiratory syndrome. Lancet 361 (9366),
1319–1325.
Pfeffer, L.M., Dinarello, C.A., Herberman, R.B., Williams, B.R., Borden,
E.C., Bordens, R., Walter, M.R., Nagabhushan, T.L., Trotta, P.P.,
Pestka, S., 1998. Biological properties of recombinant alpha-interferons:
40th anniversary of the discovery of interferons. Cancer Res. 58 (12),
2489–2499.
Sainz Jr., B., Halford, W.P., 2002. Alpha/Beta interferon and gamma
interferon synergize to inhibit the replication of herpes simplex virus
type 1. J. Virol. 76 (22), 11541–11550.
Spiegel, M., Pichlmair, A., Muhlberger, E., Haller, O., Weber, F.,
2004. The antiviral effect of interferon-beta against SARS-
Coronavirus is not mediated by MxA protein. J. Clin. Virol. 30
(3), 211–213.
Stroher, U., DiCaro, A., Li, Y., Strong, J.E., Aoki, F., Plummer, F., Jones,
S.M., Feldmann, H., 2004. Severe acute respiratory syndrome-related
coronavirus is inhibited by interferon-alpha. J. Infect. Dis. 189 (7),
1164–1167. (Electronic publication 2004 Mar 12.).
Zheng, B.J., Wong, K.H., Zhou, J., Wong, K.L., Young, B.W., Lu, L.W.,
Lee, S.S., 2004. SARS-related virus predating SARS outbreak, Hong
Kong. Emerging Infect. Dis. 10 (2), 176–178.
